Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Marubeni Invests in Healthcare Product Distributor in Africa
Japanese trading house Marubeni said on January 27 that it has invested in Phillips Healthcare, a leading distributor of healthcare products including drugs and medical devices in Sub-Saharan Africa. The strategic investment will make Phillips an equity method affiliate of…
To read the full story
Related Article
- Marubeni Pharma Targets Doubling Profits by FY2035 with 2 New Deals Each Year
November 25, 2025
- Japan’s Trading Houses Gain Ground in Pharma, Rewriting the Industry Playbook
November 10, 2025
- Marubeni Expands Pharma Sales Biz into Africa with Phillips Investment
August 20, 2025
- Marubeni Sees Drug Biz Opportunities in Global Markets with Supply-Demand Gaps
April 16, 2025
BUSINESS
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
- Guardant360 Snags Japan OK as CDx for AZ’s Camizestrant
April 28, 2026
- Meiji Begins Japan PI/II Trial of Rezurock in Pediatric GVHD
April 28, 2026
- Bayer Detects Nitrosamine in Contrast Agent, Restricts Shipments
April 27, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…